Eli Lilly said on Thursday its experimental pill, orforglipron, led to weight loss of nearly 8% at the highest dose and lowered blood sugar in patients with type 2 diabetes in a late-stage trial. The results that exceeded Wall Street expectations pushed the U.

Shares of Eli Lilly jumped 12% in premarket trading Thursday after the pharmaceutical company released Phase 3 trial results for its oral weight-loss drug that "demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines.

The latest clinical trial for Eli Lilly’s weight-loss pill suggests it’s as strong as Ozempic — with no needles required. In an exclusive interview, Dan Skovronsky, the company’s chief scientific officer,